Northern Trust Corp Sells 5,226 Shares of BioLife Solutions, Inc. $BLFS

Northern Trust Corp cut its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 1.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 405,807 shares of the medical equipment provider’s stock after selling 5,226 shares during the quarter. Northern Trust Corp owned about 0.85% of BioLife Solutions worth $9,269,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Sei Investments Co. raised its stake in BioLife Solutions by 0.5% during the first quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider’s stock valued at $2,695,000 after buying an additional 547 shares during the last quarter. Rhumbline Advisers raised its stake in BioLife Solutions by 0.7% during the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider’s stock valued at $1,901,000 after buying an additional 566 shares during the last quarter. GAMMA Investing LLC raised its stake in BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider’s stock valued at $96,000 after buying an additional 663 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in BioLife Solutions by 5.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,508 shares of the medical equipment provider’s stock valued at $532,000 after buying an additional 1,047 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in BioLife Solutions during the fourth quarter valued at $31,000. 93.24% of the stock is currently owned by institutional investors.

Insider Transactions at BioLife Solutions

In other news, CMO Todd Berard sold 10,000 shares of the company’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $25.53, for a total value of $255,300.00. Following the completion of the transaction, the chief marketing officer owned 124,618 shares of the company’s stock, valued at $3,181,497.54. This represents a 7.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $24.40, for a total value of $12,200,000.00. Following the completion of the transaction, the insider directly owned 6,707,165 shares of the company’s stock, valued at approximately $163,654,826. This trade represents a 6.94% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 2,019,020 shares of company stock valued at $47,765,813. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Price Performance

Shares of BLFS opened at $26.46 on Friday. BioLife Solutions, Inc. has a one year low of $19.10 and a one year high of $29.55. The firm has a market capitalization of $1.27 billion, a P/E ratio of -220.48 and a beta of 1.78. The business has a fifty day moving average of $23.10 and a 200 day moving average of $23.31.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.31). BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%.The business had revenue of $25.42 million during the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. Analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Analyst Ratings Changes

BLFS has been the subject of several recent analyst reports. Stephens initiated coverage on BioLife Solutions in a research note on Tuesday, July 22nd. They issued an “overweight” rating and a $30.00 price target for the company. Wall Street Zen cut BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Wednesday, May 21st. HC Wainwright restated a “buy” rating and issued a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Finally, Zacks Research upgraded BioLife Solutions to a “strong-buy” rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $31.29.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.